ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance

Core Insights - Oryzon Genomics has received a Notice of Allowance from the USPTO for its patent application related to vafidemstat, an LSD1 inhibitor aimed at treating non-aggressive symptoms of Borderline Personality Disorder (BPD) [1][3] - The U.S. patent is expected to be valid until at least 2040, with corresponding patents granted or allowed in multiple countries, enhancing Oryzon's intellectual property portfolio [2][4] Company Overview - Oryzon Genomics, founded in 2000 and headquartered in Barcelona, Spain, is a clinical-stage biopharmaceutical company specializing in epigenetics and personalized medicine for CNS disorders and oncology [5] - The company has a clinical portfolio centered around two LSD1 inhibitors: iadademstat for oncology and vafidemstat for CNS disorders, with vafidemstat being Phase III-ready for BPD [5][6] Product Development - Vafidemstat (ORY-2001) is an oral LSD1 inhibitor that shows promise in reducing cognitive impairment and neuroinflammation, with positive results in various preclinical and clinical trials for psychiatric disorders and Alzheimer's disease [6][7] - The drug is also being investigated in a Phase IIb trial for negative symptoms of schizophrenia and is part of a precision medicine approach targeting genetically defined patient subpopulations [7]